Caffarelli, principal investigator for the trial at Hoag, added, “One of the advantages of undergoing the study at Hoag is that our surgeons are highly experienced in mitral valve surgery. Caffarelli, M.D., Newkirk Family Endowed Chair in Aortic Care and director of cardiothoracic surgery and the Elaine & Robert Matranga Aortic Center at Hoag.ĭr. But for those patients who require mitral valve replacement, Hoag has the experience and expertise to offer the latest generation in valve replacement,” said Anthony D. “More than 90% of mitral valve surgeries at Hoag are performed to repair the mitral valve. To qualify for the study, patients are required to be otherwise healthy and in need of a mitral valve replacement, rather than a valve repair procedure. Carlton Heart & Vascular Institute is one of the first sites enrolling patients into the trial with plans to expand trial locations globally.īecause the valve has already received FDA approval, Hoag has already performed more than a dozen mitral valve replacements using this valve over the last eight months. The MOMENTIS study will follow patients who receive the MITRIS RESILIA valve, developed by Edwards Lifesciences using innovations that were developed to ease the orientation of the initial valve placement and bioprosthetic tissue treatment to resist calcification. (April 17, 2023) – Hoag is recruiting patients for a long-term study designed to collect real-world clinical outcomes for a new mitral valve replacement option.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |